Scalper1 News
Shire (SHPG) missed analysts’ targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker’s adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on a non-GAAP basis fell 3% to $614 million, below Wall Street views for $670 million. Revenue rose 4% to $1.56 billion, short of consensus for $1.58 billion, as the strength of the U.S. dollar cut sales Scalper1 News
Scalper1 News